Ironwood Pharmaceuticals Given Positive Rating at Aegis (IRWD)
Ironwood Pharmaceuticals (NASDAQ:IRWD)‘s stock had its “positive” rating restated by Aegis in a research note issued on Tuesday, Stock Ratings News reports.
Several other analysts have also recently commented on the stock. Analysts at Bank of America upgraded shares of Ironwood Pharmaceuticals to a “buy” rating in a research note on Wednesday, April 23rd. Analysts at Zacks downgraded shares of Ironwood Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday, April 11th. They now have a $11.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $11.54.
In other Ironwood Pharmaceuticals news, Insider Mark Currie sold 25,000 shares of the stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $11.67, for a total value of $291,750.00. Following the sale, the insider now directly owns 2,166 shares in the company, valued at approximately $25,277. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded up 11.31% during mid-day trading on Tuesday, hitting $11.32. 2,438,469 shares of the company’s stock traded hands. Ironwood Pharmaceuticals has a one year low of $8.95 and a one year high of $16.00. The stock’s 50-day moving average is $11.89 and its 200-day moving average is $11.9. The company’s market cap is $1.375 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.38) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.44) by $0.06. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $8.52 million. During the same quarter last year, the company posted ($0.87) earnings per share. Ironwood Pharmaceuticals’s revenue was up 342.4% compared to the same quarter last year. Analysts expect that Ironwood Pharmaceuticals will post $-1.38 EPS for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.